Markets:

Overview

News

Currencies

International

Treasuries

Axogen, Inc. - Common Stock (NQ:AXGN)

40.94 -0.98 (-2.35%)

Delayed Quote Updated: 1:14 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 Next >

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Via MarketBeat

Topics Intellectual Property

Axogen (AXGN) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Breast segment revenue surged over 50% year over year, driving accelerated growth.

Via The Motley Fool

Topics Earnings

AxoGen Q2 Earnings Call Highlights ↗

July 29, 2026

AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target...

Via MarketBeat

Topics Earnings

Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance ↗

July 29, 2026

Via Chartmill

Topics Earnings

Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growth ↗

June 20, 2026

Via Chartmill

Axogen Inc (NASDAQ:AXGN) Rallies on Q1 Revenue Beat and Raised 2026 Guidance ↗

April 28, 2026

Via Chartmill

Axogen Inc (NASDAQ:AXGN) Reports Q4 2025 Revenue Growth but Misses Profit Estimates ↗

February 24, 2026

Via Chartmill

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam ↗

May 14, 2026

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are...

Via MarketBeat

Axogen (AXGN) Q3 2025 Earnings Transcript ↗

April 28, 2026

Axogen (AXGN) Q3 2025 Earnings Transcript

Via The Motley Fool

Axogen (AXGN) Q1 2025 Earnings Transcript ↗

April 28, 2026

Axogen (AXGN) Q1 2025 Earnings Transcript

Via The Motley Fool

AXOGEN INC (NASDAQ:AXGN) Fits the Minervini Trend Template with Strong Growth Momentum ↗

February 17, 2026

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗

April 26, 2026

This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.

Via The Motley Fool

Topics Regulatory Compliance

Axogen (AXGN) Q2 2025 Earnings Transcript ↗

April 22, 2026

Axogen (AXGN) Q2 2025 Earnings Transcript

Via The Motley Fool

Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know ↗

March 24, 2026

This surgical solutions provider for nerve repair reported a notable insider sale amid a year of strong share price gains.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Axogen (AXGN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Axogen (AXGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

HighMark Wealth Management Buys 158,855 Shares of Axogen Stock ↗

February 24, 2026

This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

Axogen CEO Axed 25,000 Shares From His Direct Holdings ↗

January 14, 2026

The CEO of this innovative nerve regeneration company sold thousands of shares in December 2025, among multiple other insiders at the company who sold shares to close out that year.

Via The Motley Fool

Topics Regulatory Compliance

Gapping stocks in Thursday's session ↗

December 04, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

AXGN Stock Rises Pre-Market After FDA Approves Nerve Repair Graft ↗

December 04, 2025

Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.

Via Stocktwits

Topics Government

Keep an eye on the top gainers and losers in Wednesday's session. ↗

October 29, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 29, 2025

Via Benzinga

Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday ↗

October 29, 2025

Via Benzinga

Axogen Inc (NASDAQ:AXGN) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗

October 29, 2025

Axogen (AXGN) stock surged after Q3 2025 earnings beat estimates. Revenue grew 23.5% to $60.1M, while adjusted EPS of $0.12 crushed forecasts. The company also raised its full-year guidance.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 25, 2025

Via Benzinga

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗

August 25, 2025

Via Benzinga

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months ↗

August 25, 2025

FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full-year revenue outlook.

Via Benzinga

Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted ↗

August 25, 2025

The FDA's move is largely procedural, says one analyst, but it adds incremental uncertainty.

Via Investor's Business Daily

Which stocks are moving before the opening bell on Monday? ↗

August 25, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.